罗氟司特将成COPD治疗新选择

Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities, often associated with significant exposure to toxic particles and gases. The Global Burden of Disease Study shows that 174 million adults worldwide suffered from COPD in 2015, and approximately 3.3 million people died from COPD. It is estimated that COPD will rise from the fourth to the third cause of death in the world by 2030. PDE4D is a regulator of airway smooth muscle contractility, and its inhibitors have been developed as drugs to treat COPD. Currently, PDE4 inhibitors such as roflumilast are mainly used in clinical practice and will become a new treatment option for COPD.

Roflumilast, as an oral PDE4 inhibitor, will be converted into roflumilast N-oxide under the action of cytochrome enzymes after entering the body, which can effectively reduce lung inflammation, resist oxidative stress, enhance mucosal clearance and airway remodeling. In the 2014 version of the "Global Initiative for the Prevention and Treatment of COPD (GOLD) Guidelines", PDE4 inhibitors are recommended as the second option for the treatment of COPD. In cases of acute exacerbation, the use of such drugs is also recommended. In addition to its own anti-inflammatory effect, roflumilast can be used in combination with inhaled hormones to enhance the anti-inflammatory effect of the hormone and effectively relieve respiratory symptoms in patients with COPD.

For COPD patients, 500 mcg once daily, with or without food. Common side effects of this drug are flu, dizziness, diarrhea, nausea, weight loss, headache, back pain, decreased appetite, insomnia, etc.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.